12-Deoxyphorbol 13-palmitate inhibits the expression of VEGF and HIF-1α in MCF-7 cells by blocking the PI3K/Akt/mTOR signaling pathway

Yang,Ying; Cong,Huan; Han,Cuicui; Yue,Liling; Dong,Haiying; Liu,Jicheng

doi:10.3892/or.2015.4166

12-Deoxyphorbol 13-palmitate inhibits the expression of VEGF and HIF-1α in MCF-7 cells by blocking the PI3K/Akt/mTOR signaling pathway

Authors:
- Ying Yang
- Huan Cong
- Cuicui Han
- Liling Yue
- Haiying Dong
- Jicheng Liu
View Affiliations

Affiliations: The Institute of Medicine, Qiqihar Medical University, Jianhua, Qiqihar, Heilongjiang 161006, P.R. China
Published online on: July 31, 2015 https://doi.org/10.3892/or.2015.4166
Pages: 1755-1760

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vascular endothelial growth factor (VEGF) is an essential component for angiogenesis, and hypoxia-inducible factor-1α (HIF-1α), which controls the switch of glycolytic and oxidative metabolism, activates the transcription of VEGF. 12-Deoxyphorbol 13-palmitate (DP) is a compound isolated from the roots of Euphorbia fischeriana, and has been revealed to possess anticancer activity. In the present study, we found that DP is an effective inhibitor of VEGF and HIF-1α in MCF-7 cells. DP markedly reduced cell viability as determined by MTT assay. ELISA, western blotting and RT-qPCR assays indicated that DP significantly decreased the protein and mRNA expression of VEGF and the protein expression of HIF-1α, while HIF-1α mRNA remained unchanged. In addition, the entrance of HIF-1α into the nucleus was blocked after DP treatment as detected by immunofluorescence analysis. In a further study, we proved that the effects mentioned above were associated with constitutive interference of the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway. DP effectively inhibited the phosphorylation of PI3K and its downstream factors p-Akt and p-mTOR, oppositely enhanced the expression of TSC1 (hamartin) and TSC2 (tuberin), which could be reversed by the co-treatment with the PI3K inhibitor wortmannin. Moreover, the addition of wortmanin further downregulated the protein levels of VEGF and HIF-1α. The results revealed that DP inhibited the expression of VEGF and HIF-1α through the PI3K/Akt/mTOR signaling pathway, confirming that DP may be a potential therapeutic candidate for breast cancer.

View Figures

View References

1	Yersal O and Barutca S: Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol. 5:412–424. 2014. View Article : Google Scholar : PubMed/NCBI
2	Tomao F, Papa A, Zaccarelli E, Rossi L, Caruso D, Minozzi M, Vici P, Frati L and Tomao S: Triple-negative breast cancer: New perspectives for targeted therapies. Onco Targets Ther. 8:177–193. 2015. View Article : Google Scholar : PubMed/NCBI
3	Kubota Y: Tumor angiogenesis and anti-angiogenic therapy. Keio J Med. 61:47–56. 2012. View Article : Google Scholar : PubMed/NCBI
4	Xu HY, Pan YM, Chen ZW, Lin Y, Wang LH, Chen YH, Jie TT, Lu YY and Liu JC: 12-Deoxyphorbol 13-palmitate inhibit VEGF-induced angiogenesis via suppression of VEGFR-2-signaling pathway. J Ethnopharmacol. 146:724–733. 2013. View Article : Google Scholar : PubMed/NCBI
5	Goel HL and Mercurio AM: VEGF targets the tumour cell. Nat Rev Cancer. 13:871–882. 2013. View Article : Google Scholar : PubMed/NCBI
6	Kimbro KS and Simons JW: Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer. 13:739–749. 2006. View Article : Google Scholar : PubMed/NCBI
7	Zbytek B, Peacock DL, Seagroves TN and Slominski A: Putative role of HIF transcriptional activity in melanocytes and melanoma biology. Dermatoendocrinology. 5:239–251. 2013. View Article : Google Scholar
8	Li M and Kim WY: Two sides to every story: The HIF-dependent and HIF-independent functions of pVHL. J Cell Mol Med. 15:187–195. 2011. View Article : Google Scholar :
9	Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, Czernin J and Sawyers CL: Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med. 12:122–127. 2006. View Article : Google Scholar
10	Liu L, Ning X, Han S, Zhang H, Sun L, Shi Y, Sun S, Guo C, Yin F, Qiao T, et al: Hypoxia induced HIF-1 accumulation and VEGF expression in gastric epithelial mucosa cell: Involvement of ERK1/2 and PI3K/Akt. Mol Biol. 42:459–469. 2008.In Russian. View Article : Google Scholar
11	Paplomata E and O'Regan R: The PI3K/AKT/mTOR pathway in breast cancer: Targets, trials and biomarkers. Ther Adv Med Oncol. 6:154–166. 2014. View Article : Google Scholar : PubMed/NCBI
12	Gomez-Pinillos A and Ferrari AC: mTOR signaling pathway and mTOR inhibitors in cancer therapy. Hematol Oncol Clin North Am. 26:483–505. vii2012. View Article : Google Scholar : PubMed/NCBI
13	Moavero R, Coniglio A, Garaci F and Curatolo P: Is mTOR inhibition a systemic treatment for tuberous sclerosis? Ital J Pediatr. 39:572013. View Article : Google Scholar : PubMed/NCBI
14	Huang J and Manning BD: The TSC1-TSC2 complex: A molecular switchboard controlling cell growth. Biochem J. 412:179–190. 2008. View Article : Google Scholar : PubMed/NCBI
15	Fuckar D, Dekanić A, Stifter S, Mustać E, Krstulja M, Dobrila F and Jonjić N: VEGF expression is associated with negative estrogen receptor status in patients with breast cancer. Int J Surg Pathol. 14:49–55. 2006. View Article : Google Scholar : PubMed/NCBI
16	Ahluwalia A and Tarnawski AS: Critical role of hypoxia sensor - HIF-1α in VEGF gene activation. Implications for angiogenesis and tissue injury healing. Curr Med Chem. 19:90–97. 2012. View Article : Google Scholar
17	Mac Gabhann F, Qutub AA, Annex BH and Popel AS: Systems biology of pro-angiogenic therapies targeting the VEGF system. Wiley Interdiscip Rev Syst Biol Med. 2:694–707. 2010. View Article : Google Scholar : PubMed/NCBI
18	Karar J and Maity A: PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci. 4:512011. View Article : Google Scholar : PubMed/NCBI
19	Serfontein J, Nisbet RE, Howe CJ and de Vries PJ: Evolution of the TSC1/TSC2-TOR signaling pathway. Sci Signal. 3:ra492010. View Article : Google Scholar : PubMed/NCBI
20	Weinstein IB and Joe AK: Mechanisms of disease: Oncogene addiction - a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol. 3:448–457. 2006. View Article : Google Scholar : PubMed/NCBI
21	Fakhrejahani E and Toi M: Antiangiogenesis therapy for breast cancer: An update and perspectives from clinical trials. Jpn J Clin Oncol. 44:197–207. 2014. View Article : Google Scholar : PubMed/NCBI
22	Kerbel RS: Tumor angiogenesis: Past, present and the near future. Carcinogenesis. 21:505–515. 2000. View Article : Google Scholar : PubMed/NCBI
23	Reich SJ, Fosnot J, Kuroki A, Tang W, Yang X, Maguire AM, Bennett J and Tolentino MJ: Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis. 9:210–216. 2003.PubMed/NCBI
24	Fox SB, Generali DG and Harris AL: Breast tumour angiogenesis. Breast Cancer Res. 9:2162007. View Article : Google Scholar
25	Ventrice P, Leporini C, Aloe JF, Greco E, Leuzzi G, Marrazzo G, Scorcia GB, Bruzzichesi D, Nicola V and Scorcia V: Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases. J Pharmacol Pharmacother. 4(Suppl 1): S38–S42. 2013. View Article : Google Scholar : PubMed/NCBI
26	Bausero P, Ben-Mahdi M, Mazucatelli J, Bloy C and Perrot-Applanat M: Vascular endothelial growth factor is modulated in vascular muscle cells by estradiol, tamoxifen, and hypoxia. Am J Physiol Heart Circ Physiol. 279:H2033–H2042. 2000.PubMed/NCBI
27	Xiao H, Gu Z, Wang G and Zhao T: The possible mechanisms underlying the impairment of HIF-1α pathway signaling in hyperglycemia and the beneficial effects of certain therapies. Int J Med Sci. 10:1412–1421. 2013. View Article : Google Scholar
28	Chen MH, Ren QX, Yang WF, Chen XL, Lu C and Sun J: Influences of HIF-lα on Bax/Bcl-2 and VEGF expressions in rats with spinal cord injury. Int J Clin Exp Pathol. 6:2312–2322. 2013.
29	Yuan Y, Hilliard G, Ferguson T and Millhorn DE: Cobalt inhibits the interaction between hypoxia-inducible factor-α and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-α. J Biol Chem. 278:15911–15916. 2003. View Article : Google Scholar : PubMed/NCBI
30	Park SY, Jang WJ, Yi EY, Jang JY, Jung Y, Jeong JW and Kim YJ: Melatonin suppresses tumor angiogenesis by inhibiting HIF-1α stabilization under hypoxia. J Pineal Res. 48:178–184. 2010. View Article : Google Scholar : PubMed/NCBI
31	Tang N, Wang L, Esko J, Giordano FJ, Huang Y, Gerber HP, Ferrara N and Johnson RS: Loss of HIF-1α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell. 6:485–495. 2004. View Article : Google Scholar : PubMed/NCBI
32	Ahn GO, Seita J, Hong BJ, Kim YE, Bok S, Lee CJ, Kim KS, Lee JC, Leeper NJ, Cooke JP, et al: Transcriptional activation of hypoxia-inducible factor-1 (HIF-1) in myeloid cells promotes angiogenesis through VEGF and S100A8. Proc Natl Acad Sci USA. 111:2698–2703. 2014. View Article : Google Scholar : PubMed/NCBI
33	Leung KW, Ng HM, Tang MK, Wong CC, Wong RN and Wong AS: Ginsenoside-Rg1 mediates a hypoxia-independent upregulation of hypoxia-inducible factor-1α to promote angiogenesis. Angiogenesis. 14:515–522. 2011. View Article : Google Scholar : PubMed/NCBI
34	Lu N, Hui H, Yang H, Zhao K, Chen Y, You QD and Guo QL: Gambogic acid inhibits angiogenesis through inhibiting PHD2-VHL-HIF-1α pathway. Eur J Pharm Sci. 49:220–226. 2013. View Article : Google Scholar : PubMed/NCBI
35	Laughner E, Taghavi P, Chiles K, Mahon PC and Semenza GL: HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol. 21:3995–4004. 2001. View Article : Google Scholar : PubMed/NCBI
36	Xiao N, Qi XY, Tang LN, Tan LL, Chen YQ and Zhao HM: VEGF promotes cardiac stem cells differentiation into vascular endothelial cells via the PI3K/Akt signaling pathway. Artif Cells Nanomed Biotechnol. 42:400–405. 2014. View Article : Google Scholar
37	Agani F and Jiang BH: Oxygen-independent regulation of HIF-1: Novel involvement of PI3K/AKT/mTOR pathway in cancer. Curr Cancer Drug Targets. 13:245–251. 2013. View Article : Google Scholar : PubMed/NCBI
38	Lee SH, Jee JG, Bae JS, Liu KH and Lee YM: A group of novel HIF-1α inhibitors, glyceollins, blocks HIF-1α synthesis and decreases its stability via inhibition of the PI3K/AKT/mTOR pathway and Hsp90 binding. J Cell Physiol. 230:853–862. 2015. View Article : Google Scholar
39	Fang J, Ding M, Yang L, Liu LZ and Jiang BH: PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell Signal. 19:2487–2497. 2007. View Article : Google Scholar : PubMed/NCBI
40	Huang J, Dibble CC, Matsuzaki M and Manning BD: The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol. 28:4104–4115. 2008. View Article : Google Scholar : PubMed/NCBI
41	Massacesi C, di Tomaso E, Fretault N and Hirawat S: Challenges in the clinical development of PI3K inhibitors. Ann NY Acad Sci. 1280:19–23. 2013. View Article : Google Scholar : PubMed/NCBI
42	May FE: Novel drugs that target the estrogen-related receptor α: Their therapeutic potential in breast cancer. Cancer Manag Res. 6:225–252. 2014. View Article : Google Scholar